Is a tea as effective as a capsule?
Short answer
Usually not the same, because the evidence almost always belongs to the capsule. In the seven ingredients we compare here, the trials behind valerian, peppermint, lavender and chamomile (for anxiety) tested extracts or oils, while tea appears only as a traditional-use form with no trial of the tea itself. That is a gap in the evidence, not proof that tea fails, and a capsule is not automatically better either.

Why the form matters
Trials test one named preparation at one dose, and the result belongs to that preparation. Chamomile shows it clearly: the chamomile anxiety trials gave 1,500 mg a day of an extract, while the EU dose for chamomile tea is 1.5–4 g of flowers in 150 ml of boiling water, and that dose is for minor gut complaints, not anxiety.
That is why an evidence rating on an ingredient page is tied to a form. Peppermint is rated Moderate for IBS as enteric-coated oil capsules; the leaf tea is recognised by the EU regulator for indigestion and wind on long-standing use alone, and we found no controlled trial of the tea. The same holds for lavender (the anxiety evidence is for the Silexan oil) and valerian (the well-established EU use is a dry extract of 400–600 mg a dose).
Form by form
What each form is good at, and what it isn't.
| Form | What our entries show | Good for | Watch out for |
|---|---|---|---|
| Tea / infusion | Almost never the form tested. In our entries tea is a traditional-use form: valerian, peppermint, lavender, chamomile and fennel all have EU tea doses, none backed by a trial of the tea | Gentle, low-stakes use where the record is traditional; chamomile and fennel tea have EU doses for minor gut complaints | Dose is in grams of herb per cup, not a measured extract. NCCIH notes ginger trials used supplements, so the amount in tea is not comparable |
| Tincture | Not the form tested in any of the seven entries used here; EU monographs list tinctures under traditional use | Traditional-use doses exist for valerian, lavender and ginger | Contains alcohol. Strengths vary: valerian tincture single doses run from 0.3 ml to 20 ml, so labels are not interchangeable |
| Capsule or tablet (extract) | The form behind most trial evidence: valerian dry extract, chamomile extract at 1,500 mg a day for anxiety, powdered ginger root | Matching a dose that was actually studied | Shelf products vary and may not match the trial extract. A trial form is no guarantee of benefit: the best-designed valerian trials found no effect |
| Oil capsule | Enteric-coated peppermint oil for IBS; Silexan lavender oil at 80 mg a day for anxiety | The only forms with controlled trials for those two uses | Product-specific: Silexan results apply to that standardised oil, not to other lavender oils. Peppermint IBS results are mixed, with one 2021 US trial finding no difference from placebo |
| Topical or inhaled | Diluted peppermint oil on the temples for tension headache (one small trial); lavender aromatherapy for anxiety and sleep (inconsistent trials) | Uses where the oil is applied or inhaled rather than swallowed | Ginger on the skin showed no benefit for knee osteoarthritis in the review we read. Essential oil is not meant to be swallowed unless made for oral use |
Where each form does well
How to read this against a trial
When an ingredient page rates a use on a named form and dose, such as Silexan 80 mg a day for anxiety or enteric-coated peppermint oil for IBS, that rating belongs to that form and dose. If you drink a tea instead, the honest reading is that no trial of the tea exists in our entries, so the record is traditional use. The reverse also holds: a capsule of the trial form does not guarantee an effect, since the best-designed valerian trials and a 2021 US peppermint oil trial found no difference from placebo. Our methodology explains how ratings are assigned.
Questions people ask
Is a cup of tea the same dose as a capsule?
No, and the units differ. EU tea doses are grams of herb per cup (chamomile 1.5–4 g in 150 ml, peppermint leaf 1.5–3 g in 100–150 ml), while capsule doses are milligrams of extract or millilitres of oil (valerian 400–600 mg dry extract, peppermint oil 0.2–0.4 ml). NCCIH notes that most ginger trials used supplements, so the amount in tea or food is not comparable.
Is shop-bought lavender or peppermint oil the same as the capsules in the trials?
Not necessarily. The lavender anxiety results apply to Silexan specifically, not to other lavender oil products, and essential oil is not meant to be swallowed unless it is made for oral use. The peppermint IBS trials used enteric-coated capsules, which the EU monograph says should be swallowed whole about 30 minutes before meals.
Are tinctures a middle ground between tea and capsules?
The seven entries used here list tinctures only as traditional-use forms in EU monographs, for example valerian, lavender (2–4 ml, three times a day) and ginger (1.5–3 ml of a 1:10 tincture). None of them names a tincture as the form tested in trials. Tinctures contain alcohol, and valerian single doses in the monograph range from 0.3 ml to 20 ml, so follow the label.
Sources
- Meta-analysis Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006.
- Systematic review Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. 2007.
- Regulator monograph European Medicines Agency HMPC. European Union herbal monograph on Valeriana officinalis L., radix (EMA/HMPC/150848/2015). 2016.
- Meta-analysis Ingrosso MR, Ianiro G, Nee J, Lembo AJ, Moayyedi P, Black CJ, Ford AC. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022.
- Randomised controlled trial Nee J, Ballou S, Kelley JM, et al. Peppermint oil treatment for irritable bowel syndrome: a randomized placebo-controlled trial. Am J Gastroenterol. 2021.
- Regulator monograph European Medicines Agency HMPC. European Union herbal monograph on Mentha x piperita L., aetheroleum, Final – Revision 1 (EMA/HMPC/522410/2013). 2020.
- Regulator monograph European Medicines Agency HMPC. European Union herbal monograph on Mentha x piperita L., folium, Final – Revision 1 (EMA/HMPC/572705/2014). 2020.
- Systematic review Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F. Effects of lavender on anxiety: a systematic review and meta-analysis. Phytomedicine. 2019.
- Regulator/health agency NCCIH. Lavender: Usefulness and Safety. National Center for Complementary and Integrative Health.
- Regulator monograph European Medicines Agency HMPC. Community herbal monograph on Lavandula angustifolia Miller, flos (EMA/HMPC/734125/2010). 2012.
- Randomised controlled trial Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology. 2009.
- Randomised controlled trial Mao JJ, Xie SX, Keefe JR, et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine. 2016.
- Regulator monograph European Medicines Agency, HMPC. European Union herbal monograph on Matricaria recutita L., flos (EMA/HMPC/55843/2011). 2015.
- Regulator/health agency NCCIH. Ginger: Usefulness and Safety. National Center for Complementary and Integrative Health (last updated February 2025).
- Regulator monograph European Medicines Agency HMPC. European Union herbal monograph on Zingiber officinale Roscoe, rhizoma, Final Revision 1 (EMA/HMPC/885789/2022). 2025.
- Regulator monograph European Medicines Agency HMPC. European Union herbal monograph on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus (EMA/HMPC/372841/2016), Final – Revision 1. 2024.
- Randomised trial Alexandrovich I, Rakovitskaya O, Kolmo E, Sidorova T, Shushunov S. The effect of fennel (Foeniculum Vulgare) seed oil emulsion in infantile colic: a randomized, placebo-controlled study. Altern Ther Health Med. 2003.
- Systematic review Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews. 2002.
Draft, awaiting clinical review